Clinical Resources
PONS Presentation: Beyond the Horizon: Exploring the Next Frontier (No CEU)
,
Beyond the Horizon: Exploring the Next Frontier in Anticoagulation Reversal reviews and evaluates current and future agents as specific reversal antidotes for direct oral anticoagulants (DOACs) when major or life threatening hemorrhage is occurring or there is a need for emergent surgery. The DOACs include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. This presentation takes an in depth look at how DOACs affect laboratory parameters and evaluates how antidotes play a role in the reversal strategy for the anticoagulation effects produced by the DOACs.
Idarucizumab, andexanet alfa, and ciraparantag will be discussed and clinical applicability reviewed as it pertains to anticoagulation reversal in the presence of DOACs.
Presentation Objectives:
- Describe laboratory parameters impacted by direct oral anticoagulants (DOACs)
- Identify reversal strategies for life threatening hemorrhage due to DOACs
- Evaluate the current literature for the use of idarucizumab, andexanet alfa, and ciraparantag